

**Valganciclovir - Valcyte
Roche**

No. 62/03

Abbreviated Submission

8 September 2003

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The recommendation is summarised as follows:

ADVICE

Recommended for restricted use within NHS Scotland.

RECOMMENDATION

Valganciclovir has been approved for prevention of cytomegalovirus (CMV) disease in CMV-negative patients who have received a solid organ transplanted from a CMV-positive donor. It can be given once daily compared with three times daily for existing treatment, thereby improving compliance and convenience.

Use of Valganciclovir should only be initiated by physicians in transplantation or infectious disease units.

**Chairman, Scottish Medicines Consortium
8 August 2003**

Note to NHS Boards and ADTCs

The additional cost is about 10%, equivalent to around £23,000 per annum in Scotland.